Indegene Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Posted by : sachet | Wed Jan 28 2026
Click and Sign Up to Get Live Updates on Q3 Results
Indegene Q3 results for FY26 are scheduled to be announced on 29th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Indegene Q3 Results 2026 Preview
- Indegene’s revenue is expected to be in the range of ₹720.49 crore, a 4.89% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 19.63% YoY.
- Indegene. EBITDA is expected to rise to ₹111.80 crore.
- Net profit is ₹109.70 crore, a rise 19.63% YoY.
Indegene Share Performance
- Over the past six months, ITC’s share price has fallen by 12.72% to ₹478.00.
- Moreover, over the past year, the stock has decreased by 21.08%.
- Despite this weak short-term performance, ITC’s stock has delivered a financially sound 9.64% return over the past 5 years.
- As of 28th January 2026, the stock traded at ₹489.70 per share.
Key Factors to Watch for Indegene Q3 Results FY26
- Investment Portfolio Performance: Indegene’s performance is deeply tied to the value of its holdings rather than standalone operating sales volumes.
- Sales & Cash Flow Drivers (Dividend, Interest, Pledge Fees): Tracking trends in these inflows — especially how much dividends and interest contribute quarter to quarter — gives insight into the sustainability of reported revenue.
- Profitability & margins: EBITDA and PAT trends reflecting operational efficiency and product mix changes.
- Backward integration & cost efficiencies: Progress on diversifying capacity expansions to reduce import dependence and costs.
- Retail expansion & channel reach: Growth of retail outlets and direct management engagement supporting long‑term demand visibility.
Final Thoughts
Indegene will announce its Q3 FY26 results on 29th January 2026. Analysts expect 32.12% YoY revenue growth, a 13.90% fall in PAT, and a 13.90% fall in EBITDA. Indegene sits at the intersection of healthcare, technology and outsourced services — a space with strong secular demand as global pharma and biotech companies increasingly digitalise sales, regulatory and medical operations. It has demonstrated robust historical growth in revenue and profits, while also strengthening its balance sheet (even eliminating debt by 2026).
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Related Posts
Housing & Urban Development Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Greenlam Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Gillette India Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Great Eastern Shipping Company Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
